Thumbnail Image
Publication

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Stupp, R
; 
Hegi, M
; 
Gorlia, T
; 
Erridge, S
; 
Perry, J
; 
Hong, Y
; 
Aldape, K
; 
Lhermitte, B
; 
Pietsch, T
; 
Grujicic, D
... show 10 more
Citations
Altmetric:
Abstract
Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter). We aimed to assess cilengitide combined with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter.
Authors
Stupp, R
Hegi, M
Gorlia, T
Erridge, S
Perry, J
Hong, Y
Aldape, K
Lhermitte, B
Pietsch, T
Grujicic, D
Steinbach, J
Wick, W
Tarnawski, R
Nam, D
Hau, P
Weyerbrock, A
Taphoorn, M
Shen, C
Rao, N
Thurzo, L
Herrlinger, U
Gupta, T
Kortmann, R
Adamska, K
McBain, Catherine A
Brandes, A
Tonn, J
Schnell, O
Wiegel, T
Kim, C
Nabors, L
Reardon, D
van den Bent, M
Hicking, C
Markivskyy, A
Picard, M
Weller, M
Affiliation
UniversitatsSpital Zurich, Zurich, Switzerland
Description
Date
2014-09
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. 2014, 15 (10):1100-8 Lancet Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/326330
Embedded videos